Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Q&A: Stela Vujosevic shares why the staging system for diabetic eye conditions should be updated | Ophthalmology Times
Photo of Stela Vujosevic at the 2025 EURETINA meeting in Paris, France Stela Vujosevic, Md, PhD, FEBO, presented the need for a new staging system for diabetic retinopathy and diabetic macular edema at the 2025 EURETINA meeting in Paris, France.…
ExSight Ventures invests in RevOpsis Therapeutics to further AMD treatment candidate | Ophthalmology Times
Image credit: AdobeStock/jirsak ExSight Ventures invested in RevOpsis Therapeutics, a company developing a novel class of multispecific antibody-based treatments designed to address significant unmet needs in ophthalmology. The company states that initial focus will be on the developing treatment for…
Investigators share positive results of DAVIO 2 trial at EURETINA 2025 | Ophthalmology Times
(Image credit: AdobeStock/THANANIT) EYP-1901, known as the vorolanib intravitreal insert, was highlighted at the EURETINA 2025 meeting, which was held in Paris, France. In 2 presentations, researchers shared the recent results from the DAVIO 2 clinical trial. What is EYP-1901?…
Q&A: Andreas Pollreisz explains when to use and not use widefield OCT-A imaging | Ophthalmology Times
Photo of Andreas Pollreisz at the 2025 EURETINA meeting in Paris, France Andreas Pollreisz, MD, a medical and surgical retina specialist from the Medical University of Vienna, discussed widefield OCT-A imaging at the 2025 EURETINA meeting in Paris, France. He…
Ophthalmology and Visual Sciences’ Jonathan Lass joins a team studying the success of transplants of corneal tissue donated from diabetic individuals after death | CWRU Newsroom
\n \n CWRU-led research team receives $6.4 million NIH grant \n\n Crain’s Cleveland Business (subscription required): Jonathan Lass, the Charles I Thomas Professor in the Department of Ophthalmology and Visual Sciences, is part of a team of researchers awarded a…
David Almeida, MD, MBA, PhD, advances ophthalmic training with near real surgical specimens | Ophthalmology Times
David Almeida, MD, MBA, PhD, highlights near real surgical systems (NRSS), providing ophthalmologists with anatomically accurate models that replicate real surgical scenarios for training, research, and device development. (Image credit: AdobeStock/Iurii) A vitreoretinal surgeon and clinician-scientist with Erie Retina Research…
Part 5: What if? Curing any eye disease with the snap of your finger | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts in the field, in a perfect world, if they had the ability to cure one eye disease or condition in the snap of their finger, what they would choose…
Kalaris enrolling phase 1b/2 study of TH103 for nAMD | Ophthalmology Times
(Image credit: ©kwanchaift/AdobeStock) Kalaris Therapeutics announced the company is currently enrolling a phase 1b/2 multiple ascending dose (MAD) study of TH103 for the treatment of neovascular age-related macular degeneration (nAMD).1 “The phase 1b/2 study represents an important milestone in advancing…
Enhancing Vision With Small Aperture Extended Depth of Focus IOLs and Adjunctive PRK in Patients With Keratoconus
A panelist discusses how a 50-year-old male patient with stabilized keratoconus achieved excellent visual outcomes with an IC-8 small aperture IOL by targeting slight myopia to optimize the defocus curve, followed by adjunctive PRK to address central corneal astigmatism that…
Timothy Lai on the SALWEEN trial
Photo of Timothy Lai, MD, at EURETINA 2025 in Paris, France Timothy Lai, a clinical professor honorary at the Department of Ophthalmology and Visual Sciences at the Chinese University of Hong Kong, presented the one-year data from the Salween study…